Long-term survival in a patient with non-small cell lung cancer harboring a V600E mutation in the oncogene

Outcomes remain poor in advanced stage non-small cell lung cancer (NSCLC) treated with platinum-based combination chemotherapy.1-3 The identification of driver mutations in oncogenes such as EGFR and ALK, however, has shifted focus towards use of targeted molecular therapies instead. Mutations in the BRAF oncogene occur less frequently in NSCLC with an incidence of 1-4%; however, studies describing BRAF-mutant NSCLC are emerging.4-7 Here, we present the case of a lifetime non-smoker diagnosed with stage IV BRAF-mutant NSCLC who has achieved a long-term survival of nine years.

from #ORL-AlexandrosSfakianakis via simeraentaxei on Inoreader http://ift.tt/1MkfoeT
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1IXIjuE
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Pcf3kR
via IFTTT